Wallace L. Akerley,
MD
Languages Spoken: English
Wallace Akerley, MD is a medical oncologist with greater than 30 years experience as a principal investigator on numerous clinical research trials who actively cares for patients with lung cancer. He is the chairman of the Protocol Review and Monitoring Committee at Huntsman Cancer Institute (HCI), Director of the Lung Cancer Disease Center of Excellence at HCI and member of the NCCN's Steering Committee for Small Cell Lung Cancer Panel and NSCLC Panel.
Clinical Locations
Clinic 1A, Thoracic
801-213-4266
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Professor |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine (Internal Medicine) American Board of Internal Medicine (Sub: Hematology) American Board of Internal Medicine (Sub: Medical Oncology) National Board of Medical Examiners |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.9/ 5
Care provider's explanation of condition/problem
4.8/ 5
Care provider's effort to include me in decisions
4.8/ 5
Wait time at clinic
4.3/ 5
Care provider's concern for questions & worries
4.9/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
July 27, 2021
HUNTSMAN CANCER CENTER
I am talked to in ways I can best understand my treatment, risks and benefits. I also feel I am being educated more about my disease. I appreciate both being taught and listened to in a conversation dedicated to helping me.
UofU Patient
July 22, 2021
HUNTSMAN CANCER CENTER
Dr. Ackerley is always great.
UofU Patient
July 19, 2021
HUNTSMAN CANCER CENTER
Dr. Akerley may have saved my life I owe him much gratitude
UofU Patient
July 03, 2021
HUNTSMAN CANCER CENTER
Tried to explain in language that I could understand
UofU Patient
June 21, 2021
HUNTSMAN CANCER CENTER
Dr. Akerley is not only an expert knowledgeable about my disease but forward thinking of proposed treatments now and in the possible future. He is honest in his comments, straightforward in delivery and I believe committed to helping me get better. Thank you.
UofU Patient
June 14, 2021
HUNTSMAN CANCER CENTER
great
UofU Patient
June 05, 2021
HUNTSMAN CANCER CENTER
I am grateful to the moon and beyond for all the care that is given to me as "we" navigate the best possible treatments for my cancer issues. Dr. Akerley has taken the time to know me, my temperament, concerns, and goals. He is direct, honest, respectful, incredibly kind, and actively seeking the treatment best for me. I am indebted.
UofU Patient
May 23, 2021
HUNTSMAN CANCER CENTER
All Staff involved was informative, courteous and friendly
UofU Patient
May 14, 2021
HUNTSMAN CANCER CENTER
Always great bedside manner.
UofU Patient
May 10, 2021
HUNTSMAN CANCER CENTER
Dr Ackerly and his staff have continually provided exceptional insight and commitment to my treatment for cancer. I feel completely comfortable with their professional advice and their personal manner of dealing with my needs as a patient.
UofU Patient
April 25, 2021
HUNTSMAN CANCER CENTER
good
UofU Patient
April 25, 2021
HUNTSMAN CANCER CENTER
threw alot of information at me in a short time, was very hurried, most likely will not return to this provider
UofU Patient
April 19, 2021
HUNTSMAN CANCER CENTER
first visit was informative however questions concerning previous treatment in Alaska was in question. 2nd visit was a blood draw.3rd visit we saw the Dr. he seemed more positive however, all the test results were not in and we felt the visit was unnecessary. we recieved a call saying I needed to come for a biopsy and another blood draw and still no appointment date. I'm concerned as we are waiting endlessly.
UofU Patient
April 18, 2021
HUNTSMAN CANCER CENTER
Dr Akerly is one of the best doctors I have ever had!
UofU Patient
April 12, 2021
HUNTSMAN CANCER CENTER
Doctor's concern and future treatments very good, and I was satisfied!
UofU Patient
March 28, 2021
HUNTSMAN CANCER CENTER
Dr. Akerley is always so compassionate, understanding, kind, and thorough. He speaks directly to me, not my care-givers. He remembers small details about my personal life and always asks about how things have been going. He was able to give me terrific news, not only about my scans, but updated me on new therapies that would be options for me in the future if needed.
UofU Patient
March 20, 2021
HUNTSMAN CANCER CENTER
Dr Ackerly and his entire team are very pleasant and professional. it is totally refreshing knowing they are in my side and helping fight this battle.
UofU Patient
February 07, 2021
HUNTSMAN CANCER CENTER
Wallace Akereley is the best lung cancer doctor
UofU Patient
February 02, 2021
HUNTSMAN CANCER CENTER
Amazing team and all questions answered.
UofU Patient
January 29, 2021
HUNTSMAN CANCER CENTER
Dr. Akerley and his staff have treated me for stage 4 cancer for just shy of a year now. I have met with him and his team regularly and have had nothing but the best care I could have ever hoped for. His compassion, combined with his expertise, has reduced my stress levels while guiding me on a path that has enabled me to both understand my disease and work to both combat it and live with the changes it has brought to my life. The team at Huntsman has given, and reinforced, the "hope" required to stay focused on living life to its fullest.
UofU Patient
January 03, 2021
HUNTSMAN CANCER CENTER
++++!
UofU Patient
December 07, 2020
HUNTSMAN CANCER CENTER
every bad was said in a compassionate way. I can't answer the question about being included about decisions they were made. dr knew he died the next day.
UofU Patient
November 25, 2020
HUNTSMAN CANCER CENTER
not good it didn't work
UofU Patient
November 22, 2020
HUNTSMAN CANCER CENTER
Dr Akerly discussed 4 different treatment options and asked what I thought about each one.
UofU Patient
September 22, 2020
HUNTSMAN CANCER CENTER
I feel Dr. Akerley and his team are some of the most kind and compassionate people I have met. They are honest and direct and always leave the decision making up to me.
UofU Patient
August 08, 2020
HUNTSMAN CANCER CENTER
Each time I have had an appointment, they have always been attentive to my questions and concerns.
UofU Patient
July 27, 2020
HUNTSMAN CANCER CENTER
I've had excellent care at Huntsman fo the last 8 1/2 years. The staff in clinic A1 has been incredible,
UofU Patient
July 23, 2020
HUNTSMAN CANCER CENTER
This doctor and his team are the best!! They address your concerns but are also very reassuring.
UofU Patient
July 23, 2020
HUNTSMAN CANCER CENTER
The care given has prolonged my life...., but I know the end is coming.
UofU Patient
June 20, 2020
HUNTSMAN CANCER CENTER
I learned a lot my condition. The clinical staff was far more thorough and detailed in the information they provided. I felt much more knowledgeable when left.
UofU Patient
June 17, 2020
HUNTSMAN CANCER CENTER
Dr. Akerley is the very best physician I have EVER had in my life. I am so grateful to be his patient and absolutely trust his judgment and care.
UofU Patient
June 13, 2020
HUNTSMAN CANCER CENTER
Amazing experience, could not have been any better
UofU Patient
June 13, 2020
HUNTSMAN CANCER CENTER
ALWAYS excellent customer service. Great bedside manner. Answered all questions.
UofU Patient
June 05, 2020
HUNTSMAN CANCER CENTER
My Dr. is kind and informative. It is always a good experience!
UofU Patient
May 05, 2020
HUNTSMAN CANCER CENTER
Excellent appointment
UofU Patient
April 14, 2020
HUNTSMAN CANCER CENTER
I am being given the best of medical/human care, the best of explanation, and the best of treatment plans. I am treated with respect as a thinking, viable person. This boosts my confidence in healing. The health are provider, my doctor, explains things to me in ways I can understand, and in a manner that offer potential solutions This allays some of my worries. He is patient. (The whole team is patient.) And allows me the time to think about what is being said and the time to ask more questions. I cannot say enough!
UofU Patient
February 22, 2020
HUNTSMAN CANCER CENTER
I have never had a bad experience
UofU Patient
February 15, 2020
HUNTSMAN CANCER CENTER
The entire team is first rate. Listening skills and inclusiveness of patient in the process are excellent.
UofU Patient
February 15, 2020
HUNTSMAN CANCER CENTER
EXCEPTIONALLY GOOD
UofU Patient
February 01, 2020
HUNTSMAN CANCER CENTER
when you are done with your visit you are well informed on the next step of your treatments.
UofU Patient
January 26, 2020
HUNTSMAN CANCER CENTER
I have been seen at MD Anderson in TX and the Huntsman Institute has given me more hope and the provider is more optimistic.
UofU Patient
January 06, 2020
HUNTSMAN CANCER CENTER
The doctor and staff are very professional, knowledgeable, and friendly.
UofU Patient
December 25, 2019
HUNTSMAN CANCER CENTER
Doctor Akerly and his staff are terrific.
UofU Patient
December 16, 2019
HUNTSMAN CANCER CENTER
good
UofU Patient
December 16, 2019
HUNTSMAN CANCER CENTER
Awesome team, so positive and helpful !
UofU Patient
November 16, 2019
HUNTSMAN CANCER CENTER
Experience was good
UofU Patient
November 11, 2019
HUNTSMAN CANCER CENTER
Whenever I meet someone with a recent diagnosis I tell them to get to Huntsman
Wallace Akerley, MD is a medical oncologist with greater than 30 years experience as a principal investigator on numerous clinical research trials who actively cares for patients with lung cancer. He is the chairman of the Protocol Review and Monitoring Committee at Huntsman Cancer Institute (HCI), Director of the Lung Cancer Disease Center of Excellence at HCI and member of the NCCN's Steering Committee for Small Cell Lung Cancer Panel and NSCLC Panel.
Academic Locations
Huntsman Cancer Institute Research North
801-585-5986
Research Statement
Clinical research, treating patients with the investigational therapies, is the final and most important step of cancer research. Identifying new and improved and/or better tolerated therapy is the primary wish of every cancer physician. There has been a gratifying number of new cancer therapies that were evaluated at HCI and FDA approved in the recent past.
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Professor |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine (Internal Medicine) American Board of Internal Medicine (Sub: Hematology) American Board of Internal Medicine (Sub: Medical Oncology) National Board of Medical Examiners |
Research Interests
- Lung Cancer
- Non-Smoking Lung Cancer
- Radon
- Clinical Trials
Education History
| Fellowship | Dartmouth Hitchcock Medical Ctr. Hematology/Oncology Fellow, 1989 |
| Fellowship | University of Southern California Oncology Fellow, 1985 |
| Residency | University of Southern California Internal Medicine Resident, 1984 |
| Internship | University of Southern California Internal Medicine Intern, 1982 |
| Professional Medical | Brown University Medicine M.D., 1981 |
| Undergraduate | Boston University Engineering B.S., 1977 |
Selected Publications - Journal Articles
Journal Article
- Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, Kosak KM, Boucher KM, Buys SS, McGregor KA, Werner TL, Agarwal N, Weis JR, Sharma S, Ward JH, Kennedy TP, Sborov DW, Shami PJ (2021). A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC Cancer, 21(1), 510.
- Morris BB, Wages NA, Grant PA, Stukenberg PT, Gentzler RD, Hall RD, Akerley WL, Varghese TK, Arnold SM, Williams TM, Coppola V, Jones DR, Auble DT, Mayo MW (2021). MYBL2-Driven Transcriptional Programs Link Replication Stress and Error-prone DNA Repair With Genomic Instability in Lung Adenocarcinoma. Front Oncol, 10, 585551.
- Chalmers AW, Patel S, Boucher K, Cannon L, Esplin M, Luckart J, Graves N, Van Duren T, Akerley W (2019). Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up. Target Oncol, 14(4), 417-421.
- Chalmers A, Cannon L, Akerley W (2018). Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib. Oncologist, 24(7), 963-972.
- Cannon-Albright LA, Carr SR, Akerley W (2019). Population-Based Relative Risks for Lung Cancer Based on Complete Family History of Lung Cancer. J Thorac Oncol, 14(7), 1184-1191.
- Buttigliero C, Shepherd FA, Barlesi F, Schwartz B, Orlov S, Favaretto AG, Santoro A, Hirsh V, Ramlau R, Blackler AR, Roder J, Spigel D, Novello S, Akerley W, Scagliotti GV (2018). Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. Oncologist, 24(6), e251-e259.
- Kalemkerian GP, Loo BW, Akerley W, Attia A, Bassetti M, Boumber Y, Decker R, Dobelbower MC, Dowlati A, Downey RJ, Florsheim C, Ganti AKP, Grecula JC, Gubens MA, Hann CL, Hayman JA, Heist RS, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran CA, Morgensztern D, Pokharel S, Portnoy DC, Rhodes D, Rusthoven C, Santana-Davila R, Williams CC, Hoffmann KG, Hughes M (2018). NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. J Natl Compr Canc Netw, 16(10), 1171-1182.
- Carr SR, Akerley W, Cannon-Albright LA (2018). Genetic Contribution to Nonsquamous, Non-Small Cell Lung Cancer in Nonsmokers. J Thorac Oncol, 13(7), 938-945.
- Ettinger DS, Aisner DL, Wood DE, Akerley W, Bauman J, Chang JY, Chirieac LR, DAmico TA, Dilling TJ, Dobelbower M, Govindan R, Gubens MA, Hennon M, Horn L, Lackner RP, Lanuti M, Leal TA, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel SP, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M (2018). NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. J Natl Compr Canc Netw, 16(7), 807-821.
- Scagliotti GV, Shuster D, Orlov S, von Pawel J, Shepherd FA, Ross JS, Wang Q, Schwartz B, Akerley W (2017). Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study. J Thorac Oncol, 13(6), 849-854.
- Francis S, Orton A, Stoddard G, Tao R, Hitchcock YJ, Akerley W, Kokeny KE (2017). Sequencing of Postoperative Radiotherapy and Chemotherapy for Locally Advanced or Incompletely Resected Non-Small-Cell Lung Cancer. J Clin Oncol, 36(4), 333-341.
- Ou JY, Fowler B, Ding Q, Kirchhoff AC, Pappas L, Boucher K, Akerley W, Wu Y, Kaphingst K, Harding G, Kepka D (2018). A statewide investigation of geographic lung cancer incidence patterns and radon exposure in a low-smoking population. BMC Cancer, 18(1), 115.
- Gubens MA, Chuang JC, Akerley W, Langer CJ, Clment-Duchne C, San Pedro-Salcedo M, Colevas AD, Dragnev K, Socinski MA, Wakelee HA (2018). A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy. J Thorac Dis, 10(1), 219-227.
- Herde RF, Kokeny KE, Reddy CB, Akerley WL, Hu N, Boltax JP, Hitchcock YJ (2015). Primary Pulmonary Carcinoid Tumor: A Long-term Single Institution Experience. Am J Clin Oncol, 41(1), 24-29.
- Chalmers A, Jensen L, Akerley W (2017). Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report. Lung Cancer, 114, 68-69.
- Stinchcombe TE, Zhang Y, Vokes EE, Schiller JH, Bradley JD, Kelly K, Curran WJ Jr, Schild SE, Movsas B, Clamon G, Govindan R, Blumenschein GR, Socinski MA, Ready NE, Akerley WL, Cohen HJ, Pang HH, Wang X (2017). Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. J Clin Oncol, 35(25), 2885-2892.
- Akerley WL, Arnaud AM, Reddy B, Page RD (2017). Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small-cell lung cancer. Curr Med Res Opin, 33(6), 1091-1097.
- Akerley W (2017). Biomarker-Based Treatment Selection in Non-Small Cell Lung Cancer. J Natl Compr Canc Netw, 15(5S), 689-691.
- Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, DAmico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M (2017). Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 15(4), 504-535.
- Reck M, Luft A, Szczesna A, Havel L, Kim SW, Akerley W, Pietanza MC, Wu YL, Zielinski C, Thomas M, Felip E, Gold K, Horn L, Aerts J, Nakagawa K, Lorigan P, Pieters A, Kong Sanchez T, Fairchild J, Spigel D (2016). Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. J Clin Oncol, 34(31), 3740-3748.
- Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, DAmico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Swanson SJ, Stevenson J, Tauer K, Yang SC, Gregory K, Hughes M (2016). NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. J Natl Compr Canc Netw, 14(7), 825-36.
- Samadder NJ, Smith KR, Hanson H, Pimentel R, Wong J, Boucher K, Akerley W, Gilcrease G, Ulrich CM, Burt RW, Curtin K (2016). Familial Risk in Patients With Carcinoma of Unknown Primary. JAMA Oncol, 2(3), 340-6.
- Lara PN Jr, Moon J, Hesketh PJ, Redman MW, Williamson SK, Akerley WL 3rd, Hirsch FR, Mack PC, Gandara DR (2016). SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay. J Thorac Oncol, 11(3), 420-5.
- Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, DAmico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M (2016). NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw, 14(3), 255-64.
- Kurzrock R, Colevas AD, Olszanski A, Akerley W, Arteaga CL, Carson WE 3rd, Clark JW, DiPersio JF, Ettinger DS, Morgan RJ Jr, Schwartzberg LS, Venook AP, Gocke CD, Tait J, Stewart FM (2015). NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. J Natl Compr Canc Netw, 13(11), 1337-46.
- Carr SR, Akerley W, Hashibe M, Cannon-Albright LA (2015). Evidence for a genetical contribution to non-smoking-related lung cancer. Thorax, 70(11), 1033-9.
- Scagliotti G, von Pawel J, Novello S, Ramlau R, Favaretto A, Barlesi F, Akerley W, Orlov S, Santoro A, Spigel D, Hirsh V, Shepherd FA, Sequist LV, Sandler A, Ross JS, Wang Q, von Roemeling R, Shuster D, Schwartz B (2015). Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol, 33(24), 2667-74.
- Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild SE, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M, National comprehensive cancer network (2015). Non-Small Cell Lung Cancer, Version 6.2015. J Natl Compr Canc Netw, 13(5), 515-24.
- Oliver TG, Patel J, Akerley W (2015). Squamous non-small cell lung cancer as a distinct clinical entity. Am J Clin Oncol, 38(2), 220-6.
- Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Kris MG, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild S, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M (2014). Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw, 12(12), 1738-61.
- Berek JS, Edwards RP, Parker LP, DeMars LR, Herzog TJ, Lentz SS, Morris RT, Akerley WL, Holloway RW, Method MW, Plaxe SC, Walker JL, Friccius-Quecke H, Krasner CN (2014). Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study. Int J Gynecol Cancer, 24(9), 1583-9.
- Nelson RE, Stenehjem D, Akerley W (2013). A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis. Lung Cancer, 82(3), 461-8.
- Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M, National comprehensive cancer network (2013). Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw, 11(6), 645-53; quiz 653.
- Ettinger DS, Riely GJ, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M, National Comprehensive Cancer Network (2013). Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 11(5), 562-76.
- Akerley WL, Nelson RE, Cowie RH, Spinella DG, Hornberger J (2013). The impact of a serum based proteomic mass spectrometry test on treatment recommendations in advanced non-small-cell lung cancer. Curr Med Res Opin, 29(5), 517-25.
- Akerley W, Boucher K, Rich N, Egbert L, Harker G, Bylund J, Van Duren T, Reddy C (2013). A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation. Lung Cancer, 79(3), 307-11.
- Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan T, Koczywas M, Loo BW Jr, Merritt RE, Moran CA, Niell HB, OMalley J, Patel JD, Ready N, Rudin CM, Williams CC Jr, Gregory K, Hughes M, National Comprehensive Cancer Network (2013). Small cell lung cancer. J Natl Compr Canc Netw, 11(1), 78-98.
- Grossmann KF, Colman H, Akerley WA, Glantz M, Matsuoko Y, Beelen AP, Yu M, De Groot JF, Aiken RD, Olson JJ, Evans BA, Jensen RL (2012). Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme. J Neurooncol, 110(2), 257-64.
- Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW Jr, Martins R, OMalley J, Osarogiagbon RU, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, Hughes M, Gregory KM, NCCN National Comprehensive Cancer Network (2012). Non-small cell lung cancer. J Natl Compr Canc Netw, 10(10), 1236-71.
- Margolin KA, Moon J, Flaherty LE, Lao CD, Akerley WL 3rd, Othus M, Sosman JA, Kirkwood JM, Sondak VK (2012). Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res, 18(4), 1129-37.
- Ettinger DS, Akerley W, Borghaei H, Chang A, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, OMalley J, Osarogiagbon RU, Otterson GA, Patel JD, Schenck MP, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, National Comprehensive Cancer Network (2012). Malignant pleural mesothelioma. J Natl Compr Canc Netw, 10(1), 26-41.
- Poruk KE, Firpo MA, Boucher KM, Akerley WL, Neumayer LA, Sklow B, Scaife CL, Mulvihill SL (01/01/2012). Assessment of Serum Platelet Factor 4 as a Predictive Marker for VTE and as a Prognostic Biomarker in Pancreatic, Colorectal, Breast, and Lung Cancer. J Surg Res, 172(2), 242-243.
- Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow L, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan TM, Koczywas M, Moran CA, Niell HB, OMalley J, Patel JD, Ready N, Rudin CM, Williams CC Jr, National Comprehensive Cancer Network (2011). Small cell lung cancer. J Natl Compr Canc Netw, 9(10), 1086-113.
- Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, Chen Y, Costa DB, Gerber DE, Orlov S, Ramlau R, Arthur S, Gorbachevsky I, Schwartz B, Schiller JH (2011). Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol, 29(24), 3307-15.
- Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, ODay SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group, Akerley WL (2011 June 30). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med, 2011 Jun(364(26):), 2507-16.
- Akerley W, Edwards S, Wilson R, Van Duren T, Akerley D, Tranter S, Sharry S (2011 June). Awareness of Radon - Associated Health Risks in Utah. Utah's Health: An Annual Review, 16(2011), 58-60.
- Tsimberidou AM, Akerley W, Schabel MC, Hong DS, Uehara C, Chhabra A, Warren T, Mather GG, Evans BA, Woodland DP, Swabb EA, Kurzrock R (2010). Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. Mol Cancer Ther, 9(12), 3410-9.
- Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Govindan R, Grannis FW Jr, Jahan T, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, OMalley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, National Comprehensive Cancer Network (2010). Thymic malignancies. J Natl Compr Canc Netw, 8(11), 1302-15.
- Hodi FS, ODay SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebb C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 363(8), 711-23.
- Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, OMalley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ, Wood DE, Yang SC, NCCN Non-Small Cell Lung Cancer Panel Members (2010). Non-small cell lung cancer. J Natl Compr Canc Netw, 8(7), 740-801.
- Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L, Akerley W (2009). Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol, 27(31), 5255-61.
- Stinchcombe TE, Hodgson L, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Niell HB, Atkins JN, Akerley W, Green MR, Vokes EE, Cancer and Leukemia Group B (2009). Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol, 4(9), 1117-25.
- Akerley W, Boucher KM, Bentz JS, Arbogast K, Walters T (2009). A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer. J Thorac Oncol, 4(2), 214-9.
- Ettinger DS, Akerley W, Bepler G, Chang A, cheney Rt, Chirieac LR, DAmico TA, Demmy TL et al (2008). Non-small cell lung cancer. J Natl Compr Canc Netw, 6(3), 228-269.
- Kalemkerian GP, Akerley W, Downey RJ, Ettinger DS, fossella F, Grecula JC et al (2008). Small cell lung cancer. J Natl Compr Canc Netw, 6(3), 294-314.
- Kalemkerian GP, Akerley W, Downey RJ, Ettinger DS, Fossella F, Grecula JC, Jahan T, Johnson BE, Kessinger A, Koczywas M, Langer CJ, Martins R, Niell HB, Pan CC, Ramnath N, Ready N, Robert F, Williams CC Jr (2008). Small cell lung cancer. J Natl Compr Canc Netw, 6(3), 294-314.
- Ettinger DS, Akerley W, Bepler G, Chang A, Cheney RT, Chirieac LR, DAmico TA, Demmy TL, Feigenberg SJ, Figlin RA, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Patel JD, Robert F, Sugarbaker DJ, Wood DE (2008). Non-small cell lung cancer. J Natl Compr Canc Netw, 6(3), 228-69.
- Akerley W, McCoy J, Hesketh PJ, Goodwin JW, Bearden JD, Atkins JN, Chansky K, Crowley JJ, Gandara DR, SWOG (2007). Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119. J Thorac Oncol, 2(6), 526-30.
- Vokes EE, Herndon JE 2nd, Kelley MJ, Cicchetti MG, Ramnath N, Neill H, Atkins JN, Watson DM, Akerley W, Green MR (2007). Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol, 25(13), 1698-704.
- Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, Kelly K, Limentani SA, Crawford J, Reimers HJ, Axelrod R, Kashala O, Sheng S, Schiller JH (2006). Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol, 24(31), 5025-33.
- Akerley W, Safran H, Zaner K, Ready N, Mega T, Kennedy T (2006). Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer. Cancer, 107(5), 1050-4.
- Kim DW, Shyr Y, Chen H, Akerley W, Johnson DH, Choy H (2005). Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 63(4), 1029-36.
- Kim DW, Shyr Y, Shaktour B, Akerley W, Johnson DH, Choy H (2005). Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancer. Lung Cancer, 50(2), 235-45.
- Akerley W, Herndon JE Jr, Lyss AP, Choy H, Turrisi A, Graziano S, Williams T, Zhang C, Vokes EE, Green MR (2005). Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534. Clin Lung Cancer, 7(1), 47-53.
- Socinski MA, Zhang C, Herndon JE 2nd, Dillman RO, Clamon G, Vokes E, Akerley W, Crawford J, Perry MC, Seagren SL, Green MR (2004). Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. Ann Oncol, 15(7), 1033-41.
- Akerley W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, Sherman CA, Rosen DM, Hollis D, Ratain MJ, Green MR (2003). Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer, 97(10), 2480-6.
- Akerley W, Herndon J, Green M, et al (2003). Dose-Dense Weekly Paclitaxel and Pharmacologic Evaluation for Patients with Stage IIIB-IV Non-Small Cell Lung Cancer: A Phase II Trial of Cancer and Leukemia Group B (CALGB 9731/9765). Cancer, 97, 2480-6.
- Akerley W, Rathore R, Ready N, Leone L, Sikov W, Safran H, Kennedy T (2002). A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma. Cancer, 95(9), 2000-5.
- Akerley W, Butera J, Wehbe T, Noto R, Stein B, Safran H, Cummings F, Sambandam S, Maynard J, Di Rienzo G, Leone L (2002). A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone. Cancer, 94(6), 1654-60.
- Blackstock AW, Herndon JE 2nd, Paskett ED, Perry MC, Graziano SL, Muscato JJ, Kosty MP, Akerley WL, Holland J, Fleishman S, Green MR (2002). Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Natl Cancer Inst, 94(4), 284-90.
- Blackstock A, Herndon J, Paskett E, Perry M, Graziano S, Muscato, Kosty M, Akerley W, Holland J, Fleishman S, Green M (2002). Outcomes Among African-American and Non African-American Patients with Advanced Non-Small Cell Lung Cancer: A Report from the CALGB. J Natl Cancer Inst, 94(4), 284-90.
- Akerley W, Butera J, Wehbe T, Noto R, Stein B, Safran H, Cummings F, Sambandam S, Maynard J, Di Rienzo G, Leone L (2002). A Multiinstitutional, Concurrent Chemoradiation Trial of Strontium-89, Estramustine, and Vinblastine for Hormone Refractory Prostate Carcinoma Involving Bone. Cancer, 94(6), 1654-1660.
- Makarovskiy A, Siryaporn E, Hixon D, Akerley W (2002). Survival of Docetaxel-resistant Prostate Cancer Cells Depends on Phenotype Alterations and Continuity of Drug Exposure. Cell Mol Life Sci, 59, 1198-1211.
- Akerley W, Rathore R, Ready N, Leone L, Sikov W, Safran H, Kennedy T (2002). A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma. Cancer, 95(9), 2000-5.
- Akerley W (2001). Recent developments in weekly paclitaxel therapy in lung cancer. Curr Oncol Rep, 3(2), 165-9.
- Gurevich I, Akerley W (2001). Treatment of the Jaundiced Patient with Breast Carcinoma. Cancer, 91(4), 660-663.
- Akerley W (2001). Recent Development in Weekly Paclitaxel Therapy of Lung Cancer. Curr Oncol Rep, 3(2), 165-169.
- Wanebo H, Chougule P, Ready N, Safran H, Akerley W, Koness R, McRae R, Nigri P, Leone L, Kennedy T, Webber B (2001). Surgical Resection is Necessary to Maximize Tumor Control In Function Preserving, Aggressive Chemoradiation Protocols for Advanced Squamous Cancer of the Head and Neck (Stage III and IV). Ann Surg Oncol, 8, 644-50.
- Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, Hussain A, Small EJ, Vogelzang NJ (2001). Phase II Study of Docetaxel, Estramustine, and Low-dose Hydrocortisone in Men with Hormone-refractory Prostate Cancer: a final report of CALGB 9780. J Clin Oncol, 19(9), 2509-16.
- Jaeckle KA, Phuphanich S, Bent MJ, Aiken R, Batchelor T, Campbell T, Fulton D, Gilbert M, Heros D, Rogers L, ODay SJ, Akerley W, Allen J, Baidas S, Gertler SZ, Greenberg HS, LaFollette S, Lesser G, Mason W, Recht L, Wong E, Chamberlain MC, Cohn A, Glantz MJ, Gutheil JC, Maria B, Moots P, New P, Russell C, Shapiro W, Swinnen L, Howell SB (2001). Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br J Cancer, 84(2), 157-63.
- King TC, Akerley W, Fan AC, Moore T, Mangray S, Hsiu Chen M, Safran H (2000). p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma. Cancer, 89(4), 769-73.
- Akerley W 3rd (2000). Paclitaxel in advanced non-small cell lung cancer : an alternative high-dose weekly schedule. Chest, 117(4 Suppl 1), 152S-155S.
- Akerley W (2000). Secondary Leukemia: Twice is a Coincidence? Cancer, 88(3), 497-9.
- Dupuy D, Zagoria R, Akerley W, Mayo-Smith W, Kavanagh P, Safran H (2000). Percutaneous Radiofrequency Ablation of Malignancies in the Lung. Am J Roentgenol Radium Ther Nucl Med, 174(1), 57-9.
- Akerley W (2000). Paclitaxel in Advanced Non-small Cell Lung Cancer: An Alternative High-dose Weekly Schedule. Chest, 117:4 (suppl 1), 152-5.
- King T, Akerley W, Fan A, Walsh K, Mangray S, Chen M, Safran H (2000). P53 Mutations Do Not Predict Response to Paclitaxel for Metastatic Non-Small Cell Lung Cancer. Cancer, 89(4), 769-73.
- Dupuy DE, Zagoria RJ, Akerley W, Mayo-Smith WW, Kavanagh PV, Safran H (2000). Percutaneous radiofrequency ablation of malignancies in the lung. AJR Am J Roentgenol, 174(1), 57-9.
- Akerley W, Choy H (1999). Single-agent paclitaxel and radiation for non-small cell lung cancer. Semin Radiat Oncol, 9(2 Suppl 1), 85-9.
- Wanebo HJ, Chougule P, Ready N, Koness RJ, Akerley W, McRae R, Nigri P, Leone L, Webber B, Safran H (1999). Preoperative paclitaxel, carboplatin, and radiation therapy in advanced head and neck cancer (stage III and IV). Semin Radiat Oncol, 9(2 Suppl 1), 77-84.
- Chougule PB, Akhtar MS, Akerley W, Ready N, Safran H, McRae R, Nigri P, Bellino J, Koness J, Radie-Keane K, Wanebo H (1999). Chemoradiotherapy for advanced inoperable head and neck cancer: A phase II study. Semin Radiat Oncol, 9(2 Suppl 1), 58-63.
- Chougule P, Akhtar M, Akerley W, Ready N, Safran H, McRae R, Nigri P, Bellino J, Koness R, Radie-Kane K, and Wanebo H (1999). Chemoradiotherapy for Advanced Inoperable Head and Neck Cancer: A Phase II Study. Semin Radiat Oncol, 9(2) suppl 1, 58-63.
- Akerley W and Choy H (1999). Single Agent Paclitaxel and Radiation for Non-Small Cell Lung Cancer. Semin Radiat Oncol, 9(2) suppl 1, 85-89.
- Wanebo H, Chougule P, Ready N, Koness R, Akerley W, McRae R, Nigri P, Leone L, Webber B, Safran H (1999). Preoperative Paclitaxel, Carboplatin and Radiation Therapy in Advanced Head and Neck Cancer. Semin Radiat Oncol, 9(2) suppl 1, 77-84.
- Glantz M, Kim L, Choy H, Akerley W (1999). Concurrent Chemotherapy and Radiotherapy in Patients with Brain Tumors. Oncology, 13(10) suppl 5, 78-82.
- Choy H, Akerley W, Safran H, Graziano S, Chung C, Williams T, Cole B, Kennedy T (1998). Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol, 16(10), 3316-22.
- Choy H, Safran H, Akerley W, Graziano SL, Bogart JA, Cole BF (1998). Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res, 4(8), 1931-6.
- Glantz MJ, Cole BF, Recht L, Akerley W, Mills P, Saris S, Hochberg F, Calabresi P, Egorin MJ (1998). High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J Clin Oncol, 16(4), 1561-7.
- Recht LD, Glantz MJ, Meitner P, Glantz L, Akerley W, Wahlberg L, Saris S, Cole BF (1998). Unexpected in vitro chemosensitivity of malignant gliomas to 4-hydroxyperoxycyclophosphamide (4-HC). J Neurooncol, 36(3), 201-8.
- Akerley W (1998). Oncology: Combined Modalilty Therapy in Non-Small Cell Lung Cancer. Disease Management Digest, 2(3), 14-15.
- Clamon G, Herndon J, Akerley W, Green M (1998). Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer: a phase II trial of Cancer and Leukemia Group B. Lung Cancer, 19(1), 25-9.
- Akerley W, Glantz M, Choy H, Rege V, Sambandam S, Joseph P, Yee L, Rodrigues B, Wingate P, Leone L (1998). Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol, 16(1), 153-8.
- Chougule P, Wanebo H, Akerley W, McRae R, Nigri P, Leone L, Safran H, Ready N, Koness RJ, Radie-Keane K, Cole B (1997). Concurrent paclitaxel, carboplatin, and radiotherapy in advanced head and neck cancers: a phase II study--preliminary results. Semin Oncol, 24(6 Suppl 19), S19-57-S19-61.
- Wanebo HJ, Chougule P, Akerley WL 3rd, Koness RJ, McRae R, Nigri P, Leone L, Ready N, Safran H, Webber B, Cole B (1997). Preoperative chemoradiation coupled with aggressive resection as needed ensures near total control in advanced head and neck cancer. Am J Surg, 174(5), 518-22.
- Akerley W, Sikov WM, Cummings F, Safran H, Strenger R, Marchant D (1997). Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report. Semin Oncol, 24(5 Suppl 17), S17-87-S17-90.
- Akerley W, Choy H, Safran H, Sikov W, Rege V, Sambandam S, Wittels E (1997). Weekly paclitaxel in patients with advanced lung cancer: preliminary data from a phase II trial. Semin Oncol, 24(4 Suppl 12), S12-10-S12-13.
- Safran H, King TP, Choy H, Hesketh PJ, Wolf B, Altenhein E, Sikov W, Rosmarin A, Akerley W, Radie-Keane K, Cicchetti G, Lopez F, Bland K, Wanebo HJ (1997). Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study. J Clin Oncol, 15(3), 901-7.
- Choy H, Akerley W, Safran H, Graziano S (1997). Concurrent Weekly Paclitaxel and Radiation Therapy for Locally Advanced NSCLC. Lung Cancer, 18(S2), 152.
- Choy H, King T, Akerley W, Safran H (1997). Paclitaxel and Concurrent Radiation for Lung, Pancreatic and Gastric Carcinomas: Significance of p53 Gene Mutations for Treatment Response. Semin Radiat Oncol, 7(3), s77-81.
- Choy H, Akerley W, Safran H, Clark J, Rege V, Papa A, Glantz M, Puthawala Y, Soderberg C, Leone L (1997). Phase I Trial of Outpatient Weekly Paclitaxel and Concurrent Radiation Therapy for Advanced Non-Small Cell Lung Cancer. Classic Papers and Current Comments, 2(1), 167-71.
- Choy H, Akerley W, Devore R (1997). Paclitaxel in Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. Advances in Oncology, 13(4), 17-24.
- Makarovskiy A, Ackerley W, Wojcik W, Halpert G, Stein B, Carreiro M, Hixson D (1997). Application of Immunomagnetic Beads in Combination with RT-PCR for the Detection of Circulating Prostate Cancer Cells. J Clin Lab Anal, 11, 346-50.
- Glantz MJ, Choy H, Akerley W, Kearns CM, Egorin MJ, Rhodes CH, Cole BF (1996). Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and response. Semin Oncol, 23(6 Suppl 16), 128-35.
- Choy H, Akerley W, Safran H, Graziano S, Chung C (1996). Paclitaxel plus carboplatin and concurrent radiation therapy for patients with locally advanced non-small cell lung cancer. Semin Oncol, 23(6 Suppl 16), 117-9.
- Akerley W (1996). Phase I/II trial of weekly paclitaxel in patients with advanced lung cancer. Semin Oncol, 23(6 Suppl 16), 55-8.
- Akerley W 3rd, Glantz M, Choy H (1996). Preliminary results of a phase I study of weekly paclitaxel infusion in patients with non-small cell lung cancer. Semin Oncol, 23(5 Suppl 12), 14-8.
- Choy H, Akerley W, Glantz M, Safran H, Graziano S, Chung C (1996). Concurrent Paclitaxel and Radiation Therapy for Solid Tumors. Cancer Control, 3(4), 310-318.
- Glantz MJ, Cole BF, Friedberg MH, Lathi E, Choy H, Furie K, Akerley W, Wahlberg L, Lekos A, Louis S (1996). A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology, 46(4), 985-91.
- Glantz M, Choy H, Akerley W, Kearns C, Egorin M, Rhodes H, Cole B (1996). Weekly Paclitaxel With and Without Concurrent Radiation Therapy: Toxicity, Pharmacokinetics and Response. Semin Oncol, 23(6) Suppl 16, 128-135.
- Akerley W, Glantz M, Choy H (1996). Phase I Study of Weekly Outpatient Paclitaxel in Advanced and Metastatic Non-small Cell Lung Cancer. Semin Oncol, 23(5), Suppl 12, 14-18.
- Clark J, Sikov W, Cummings F, Browne M, Akerley W, Wanebo H, Weitberg A, Kennedy T, Cole B, Bigley J, Beitz J, Darnowski J (1996). Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer. J Cancer Res Clin Oncol, 122(9), 554-8.
- Glantz MJ, Choy H, Kearns CM, Akerley W, Egorin MJ (1995). Weekly, outpatient paclitaxel and concurrent cranial irradiation in adults with brain tumors: preliminary results and promising directions. Semin Oncol, 22(5 Suppl 12), 26-32.
- Glantz MJ, Hall WA, Cole BF, Chozick BS, Shannon CM, Wahlberg L, Akerley W, Marin L, Choy H (1995). Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status. Cancer, 75(12), 2919-31.
- Akerley W, Choy H (1995). Concurrent paclitaxel and thoracic radiation for advanced non-small cell lung cancer. Lung Cancer, 12 Suppl 2, S107-15.
- Choy H, Akerley W, Safran H, Clark J, Rege V, Papa A, Glantz M, Puthawala Y, Soderberg C, Leone L (1994). Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol, 12(12), 2682-6.
- Miller ME, Dores GM, Thorpe SL, Akerley WL (1994). Paradoxical influence of estrogenic hormones on platelet-endothelial cell interactions. Thromb Res, 74(6), 577-94.
- Akerley WL 3rd, Moritz TE, Ryan LS, Henderson WG, Zacharski LR (1993). Racial comparison of outcomes of male Department of Veterans Affairs patients with lung and colon cancer. Arch Intern Med, 153(14), 1681-8.
- Posner M, Martin A, Slapak CA, Clark JW, Cummings FJ, Robert NJ, Sikov W, Akerley W (1992). A phase II trial of continuous infusion cisplatin and 5-fluorouracil with oral calcium leucovorin in colorectal carcinoma. Am J Clin Oncol, 15(3), 239-41.
- Akerley WL 3rd, Guyre PM, Davis BH (1991). Neutrophil activation through high-affinity Fc gamma receptor using a monomeric antibody with unique properties. Blood, 77(3), 607-15.
- Grunberg SM, Ehler E, McDermed JE, Akerley WL (1988). Oral metoclopramide with or without diphenhydramine: potential for prevention of late nausea and vomiting induced by cisplatin. J Natl Cancer Inst, 80(11), 864-8.
- Grunberg SM, Akerley WL, Krailo MD, Johnson KB, Baker CR, Cariffe PA (1986). Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatinum-induced emesis. Cancer Invest, 4(5), 379-85.
Review
Editorial
Letter
Huntsman Cancer Institute News
The Scope & Other Podcasts
- Radon is a Silent Killer
- Physicians Want Lung Cancer Patients to Know This After a Positive Diagnosis
- Better Alternatives to Chemotherapy Emerging
- Silent Killer: Radon Is the 2nd Leading Cause of Lung Cancer
- Dr. Akerley
- Clinical Trials at HCI
- Wallace Akerley - Radon: A Stealthy Assassin
- Wallace Akerley, MD
- Are You Breathing Radon?